



**FLORIDA SOCIETY OF CLINICAL ONCOLOGY BLAST FAX –September 10, 2009**

**FLASCO WEBSITE: [www.flasco.org](http://www.flasco.org)**

**FLASCO CLINICAL TRIALS NETWORK WEBSITE: [www.fctn.org](http://www.fctn.org)**

**MESSAGE FROM THE PRESIDENT: Gerald Robbins, MD**

FLASCO is honored to have one of our own members, Dr. Rogerio Lilenbaum, running for the ASCO Nominating Committee.

**Fellows Business of Oncology Program**

I am extremely pleased to report that the University of Florida HemOnc Fellowship Program has agreed to partner with FLASCO to provide Business of Oncology Programs to their Fellows. Our first presentation will be in November 2009. These Sessions will be on Wednesday mornings at the University from 7:30 – 9:00 am. In addition Mayo in Jacksonville and the University of Miami also have expressed interest in participating with FLASCO in this initiative.

Topics selected for these presentations include:

- Utilization and Responsibilities of Mid-Level Providers
- Professional Contract Negotiations for Entering Practice (as it relates to both Private and Academic position)
- Billing and Coding in HemOnc
- Maintenance of Certification and Credentialing
- Finances of Research in Practice

**Please contact the FLASCO Executive Director if you would be willing to provide a presentation on one of the topics listed above.**

**PROGRAM COMMITTEE UPDATES: Jose Lutzy, MD, Chairman**

**Business of Oncology Summit:**

FLASCO will be holding its 1<sup>st</sup> Annual Business of Oncology Summit on October 3, 2009, in Tampa. FLASCO has partnered with Abraxis BioScience to hold this very exciting and timely conference. Topics that will be presented by expert speakers are as follows: Financial Planning, Managed Care Contract Negotiations, Succession Planning, Clinical Pathway Development and Implementation, Utilizations and Responsibilities of the PA/ARNP, and Strategic Planning: What, Why and How.

**JOIN US** for this professional forum that explores what cancer care leaders are doing to achieve a future vision of successful cancer care delivery, focusing on innovative business practices, clinical integration, and patient-centric approaches to providing care. For more information on the Business of Oncology Summit or to register, please go online to [www.flasco.org](http://www.flasco.org). The meeting announcement and registration form are available there. **Registration deadline is September 15, 2009**

**2010 PA/NP Conference:**

We are pleased to announce that FLASCO will sponsor its Second Annual Conference for PAs/NPs on March 26, 2010, in Miami. Special thanks are extended to Dayne Alonso, PA-C and Michele Taffaro Neskey, PA-C for agreeing to serve as Co-Chairmen of the Workgroup to plan this Conference.

**CLINICAL PRACTICE COMMITTEE: Thomas Gaddis, MD, Chairman**

**National Guideline Clearinghouse: Agency for Healthcare Research and Quality (AHRQ)**

**American College of Radiology:**

ACR Appropriateness Criteria® endometrial cancer of the uterus. This updates a previously published guideline summary. [http://www.guideline.gov/summary/summary.aspx?view\\_id=1&doc\\_id=13689](http://www.guideline.gov/summary/summary.aspx?view_id=1&doc_id=13689)

## **REMINDER - Continuing Medical Education for Licensure Reregistration**

### **Florida MD—First time license renewal:**

One hour HIV/AIDS, 2 hours in prevention of medical errors. **Second and subsequent renewals:**

Two hours in prevention of medical errors. **Every third renewal:** Forty hours, including 2 hours in prevention of medical errors and 2 hours in domestic violence CME. **Note:** End-of-life care and palliative care can no longer be completed in lieu of HIV/AIDS or domestic violence courses.

All CME must be AMA PRA Category 1 Credit™, except for domestic violence and prevention of medical errors. Domestic violence and prevention of medical errors courses offered by any state or federal government agency or professional association, including any provider of AMA PRA Category 1 Credit™, is acceptable.

### **Florida DO—First time license renewal:**

One hour HIV/AIDS, risk management, Florida laws and rules, controlled substances; 2 hours domestic violence and prevention of medical errors. Of the remaining required **and subsequent renewals:** One hour each in risk management, Florida laws and rules, and controlled substances; 2 hours each in domestic violence and prevention of medical errors. **Every third renewal:** 2 hours of domestic violence. **For each license renewal,** of the remaining required hours at least 20 must be AOA Category 1-A; all other hours (including those in the required content categories) can be either AMA PRA Category 1 Credit™ or AOA Category 1-A credit.

Continuing medical education with regard to risk management, Florida laws and rules, controlled substances, and the prevention of medical errors must be obtained by completing live, participatory attendance courses.

## **DRUG UPDATES:**

### **Zevalin**

Spectrum Pharmaceuticals announced that ZEVALIN(R) (ibritumomab tiuxetan), a CD20-directed radiotherapeutic antibody, received approval from the U.S. Food and Drug Administration (FDA) for an expanded label for the treatment of patients with previously untreated follicular non-Hodgkin's Lymphoma (NHL), who achieve a partial or complete response to first-line chemotherapy.

## **FDA UPDATES:**

### **FDA approves new Hologic therapy**

Hologic Inc. announced that the Food and Drug Administration approved a new version of its MammoSite system, which delivers radiation seeds to prevent recurrences of breast cancer. The company said it plans to launch the MammoSite ML by Dec. 26, the end of its fiscal fourth quarter.

The agency approved the MammoSite ML radiation therapy system, which allows physicians to better target specific areas of tissue than the original MammoSite system, the company said. MammoSite devices include balloon catheters that are inserted into the body after a tumor has been removed. Inside the catheter is a pellet of radioactive material. The radiation seed is left inside the body for five days, delivering radiation to the areas the cancer is most likely to return, Hologic said. The treatment is intended to prevent a recurrence while not harming healthy tissue.

### **Myfortic (mycophenolic acid)**

GlaxoSmithKline and FDA notified healthcare professionals that cases of Pure Red Cell Aplasia (PRCA) have been reported in patients treated with Myfortic. The WARNINGS and ADVERSE REACTIONS sections of the CellCept Prescribing Information have been revised to reflect this new safety information. For more information, go to: <http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm181306.htm>

## **FCSO UPDATES:**

### **October update to the 2009 Medicare physician fee schedule database**

**Modified:** 9/3/2009 **Business:** Part A, Part B **Location:** FL, PR, USVI

This article was revised on September 2, 2009, to revise the CR release date, transmittal number, and Web address for accessing CR 6617. The article also now shows an effective date of September 1, 2009, for codes G9141 and G9142. [MM6617] [http://medicare.fcso.com/Fee\\_news/156081.asp](http://medicare.fcso.com/Fee_news/156081.asp)

### **October 2009 Quarterly HCPCS update**

The October 2009 quarterly update, there is one new code payable for Medicare and no deletions of HCPCS codes. Effective for claims with dates of service on or after October 1, 2009, the following HCPCS code will be payable for Medicare:

Q2024 Injection, bevacizumab, 0.25 mg

Here is the link to the MLN Matters article [MM6594](http://www.cms.hhs.gov/MLNMattersArticles/downloads/MM6594.pdf)  
<http://www.cms.hhs.gov/MLNMattersArticles/downloads/MM6594.pdf>

### **MLM UPDATES:**

#### **Revised:**

MM6617 – **October Update to the 2009 Medicare Physician Fee Schedule Database (MPFSDB)**  
<http://www.cms.hhs.gov/MLNMattersArticles/downloads/MM6617.pdf>

### **EDUCATIONAL OPPORTUNITY:**

Sanofi-Aventis cordially invites you to dinner and discussion on “The role of Taxotere (docetaxel) injection concentrate in breast cancer” with: Shou-Ching Tang MD, Professor and Chief, Denver Health Medical Center, University of Colorado, Denver, CO and Professor of Medicine, Division of Medical Oncology, University of Colorado, Aurora, CO

**Date:** 09/21/2009 – 6:30 PM – 8:30 pm

**Location:** Tampa Westshore area - The Palm Restaurant, 205 Westshore Plaza Drive  
Tampa, FL - **Phone:** 813-849-7256

To register please contact:

Lisa Tawil - 813) 416-8109 Sheryl King –(813) 220-2428 Vivian Curran - (727) 251-2726  
**Email:** [Lisa.tawil@sanofi-aventis.com](mailto:Lisa.tawil@sanofi-aventis.com) - [Sheryl.king@sanofi-aventis.com](mailto:Sheryl.king@sanofi-aventis.com) - [Vivian.curran@sanofi-aventis.com](mailto:Vivian.curran@sanofi-aventis.com)  
**RSVP by Date:** 09/17/2009

### **BUSINESS Q & A: (Source: The Phipps Wealth Management Group)**

Q. My tax advisor seldom suggests anything and basically is a tax return preparer. How can I get him/her to really be a TAX ADVISER?

A. We have a series of written questions and issues we can share with you to give him/her. They normally generate some action. Per your direction, we can speak with them, too.

For more information you may contact: 561-276-1635 Direct - 877-276-1635 Toll Free – fax: 561-922-3275 - E-mail: [jeffrey\\_phippsr@ml.com](mailto:jeffrey_phippsr@ml.com) - <http://fa.ml.com/PhippsGroup/>

### **CORPORATE MEMBERSHIP/SPONSORSHIP: (January 1 – December 31, 2009)**

FLASCO Members extend a big thanks to all of our 2009 Corporate Members/Sponsors (Companies listed below have either paid 2009 dues or have submitted letters of intent)

**PLATINUM**  
AMGEN

**GOLD**  
Abraxis Oncology

**SILVER**  
OSI Pharmaceuticals

**BRONZE**  
Genzyme

Bayer/Onyx	Bristol Myers Squibb	US Oncology
Cephalon Oncology	Genomic Health	
Eli Lilly	Wyeth	
Oncology Supply/ION	Roche	
Sanofi-Aventis	Millennium	
Celgene	Allos Therapeutics,	
	Inc.	
Eisai, Inc.	ImClone	
Ortho Biotech		
Genentech		
GlaxoSmithKline		
The Phipps Wealth		
Management Group		
Novartis		
Astra Zeneca		
Pfizer		

**FLASCO 2009 MEETINGS:**

**October 3, 2009** – FLASCO Business of Oncology Summit - Tampa

**November 6-7, 2009** – FLASCO Fall Meeting – Tampa Airport Marriott Hotel

**March 5-6, 2010** – FLASCO Spring Meeting and Annual Session – Tampa Airport Marriott Hotel

**March 26, 2010** – PA/NP Conference – Miami

**FLASCO CO-SPONSORED MEETINGS:**

**January 16, 2010** - Clinical Breakthroughs & Challenges in Hematologic Malignancies – Grand Floridian Resort – Lake Buena Vista - For more information, call (813) 745-1247 or e-mail: [Melissa.Pearson@MOFFITT.org](mailto:Melissa.Pearson@MOFFITT.org)

**OTHER MEETINGS/WEBCASTS**

**September 11-12, 2009** - ASH State of the Art Symposium – Chicago, IL – For more information: <http://hematology.org/meetings/sas/index.cfm>.

**September 22-25, 2009** - ACCC's 26th National Oncology Economics Conference - - Hyatt Regency Minneapolis on Nicollet Mall, 1300 Nicollet Mall, Minneapolis, MN 55403 - 612.370.1234

**October 6-7, 2009** - ASCO Electronic Health Records Symposium - Harnessing the EHR: *From Incentives to Sustainability*- San Francisco Marriott Hotel - to register: [www.asco.org/ehrsymposium](http://www.asco.org/ehrsymposium)

**Nov 1-5, 2009** - ASTRO's Annual Meeting – Chicago

**November 13 - 15, 2009** - Oncology Nursing Society Fall (ONS) – Tampa

**December 5-8, 2009** - ASH Annual Meeting – Ernest N. Morial Convention Center, New Orleans, LA – For more information: <http://hematology.org/meetings/2009/index.cfm>

**December 10 - 13, 2009** - San Antonio Breast Cancer Symposium (SABCS) San Antonio, TX

**Feb 25-27, 2010** - American College of Radiation Oncology Annual Meeting – Lake Buena Vista, FL

**March 17-20, 2010** - ACCC's 36th Annual National Meeting - -Baltimore Marriott Waterfront

**FLASCO Contact Info:**

Dorothy Green Phillips, Executive Director - Phone: 1.813.349.4410 – [Dorothy.Green@cancer.org](mailto:Dorothy.Green@cancer.org)

July 29, 2009